|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
3rd Floor,South San Francisco,CA,US
|
|
CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.
|
CODA Biotherapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used CODA Biotherapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact CODA Biotherapeutics customer service number in your country click here to find.
Mike Narachi is the CEO of CODA Biotherapeutics.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.